In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with John Fowler, President & CEO at Pii (Pharmaceutics International, Inc.)

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with John, covering:

• How a competitive family environment and navigating flight school in the Navy equipped him for a successful career
• Why a CDMO business is like managing chaos... under strict regulations
• The silver lining of the pandemic - quality time with his family
• Why he decided to leave Johnson Matthey after 30 years and take a 'title' step back
• Bringing PII back to its former glory and rebuilding a management team

John Fowler brings more than 30 years of pharmaceutical and chemical industry experience to Pii. He most recently served as President and Chief Operating Officer of Piramal Pharma Solutions, a CDMO serving generic companies worldwide. Before joining Piramal, he was the Divisional CEO of the Global Fine Chemical business at Johnson Matthey.

Mr. Fowler also held senior leadership roles in several business verticals at JM, including Pharmaceutical Materials and Services, Environmental Catalysts, and Technologies. He has a Chemical Engineering degree from Bucknell University and an MBA from St. Joseph University.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• • Dirk Lange, CEO at Pyramid Labs
  • Brett Alderson, President & Site Leader at NovaCina
  • John Cameron, Director, Global Injectables Platform at Corden Pharma
  • Janet Hoogstraate, CEO at NorthX Biologics

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dirk, Brett, John & Janet, focusing on:

• Maximizing GLP-1 manufacturing capacity: Discussing Novo Nordisk’s recent acquisition of Catalent’s manufacturing facilities to bolster GLP-1 production capabilities
• Industry consolidation: What this acquisition means for the pharmaceutical outsourcing industry and its impact on competition among CDMOs
• Meeting surging demand: Exploring how this move positions Novo Nordisk to respond to the rapidly increasing demand for GLP-1 receptor agonists, like those used in diabetes and obesity treatments
• Strategic manufacturing: The implications of integrating Catalent’s capabilities into Novo Nordisk’s operations and what it means for the broader CDMO sector

With GLP-1 drugs at the forefront of diabetes and obesity treatment, Novo Nordisk's strategic acquisition of Catalent aims to strengthen its supply chain and boost production capacity to meet global demand. Our guests provide in-depth insights into how this acquisition could shape the future of drug development and outsourcing across the industry.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Stevenson, Independent Director and Pharma industry veteran.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:

• Bringing an outsourcing model from UpjohnPharmacia into Pfizer and then driving manufacturing out of Pfizer into CDMOs without compromising on quality or IP
• Behind the scenes of Pfizer's mammoth acquisitions of Wyeth and Hospira
• The failure to spend too much time setting up a reliable, high-quality outsourcing network in China
• The different perspectives of being 'the mayor of one huge site' to having a diversified, helicopter view across several
• Switching from buy-side external outsourcing to running Pfizer's CDMO division Pfizer CentreOne
• Don't be penny-wise and pound-foolish when balancing the onshoring manufacturing conundrum and how price controls in the US will impact all aspects of the industry

Peter Stevenson is a leader in the pharmaceutical industry with extensive manufacturing and commercial experience. He was a Pfizer’s Global Manufacturing Leadership Team member, responsible for global procurement, global external supply, and a portfolio of Pfizer's internal manufacturing sites in North America, Europe, and Asia. Today, he is a Non-Executive Independent Board Member at Piramal Pharma.

Later, Mr. Stevenson served as General Manager of Pfizer’s contract manufacturing business and Value Stream Leader for the Injectables and Hospital Products Value Stream. Mr. Stevenson recently retired from Pfizer and serves as the Board Vice-Chair for Uniting to Combat Neglected Tropical Diseases and Chair of the Governance Committee.

Earlier in his career, Mr. Stevenson held positions at Rhone Poulenc and Celanese, including a 3-year expatriate assignment in France. He has a Bachelor’s degree in Arts from Gettysburg College, Pennsylvania.

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.